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Background: Anal fistula occurs in approximately one in three patients with Crohn’s disease and is
typically managed through a multimodal approach. The optimal surgical therapy is not yet clear. The
aim of this systematic review was to identify and assess the literature on surgical treatments of Crohn’s
anal fistula.
Methods: A systematic review was conducted that analysed studies relating to surgical treatment of
Crohn’s anal fistula published on MEDLINE, Embase and Cochrane databases between January 1995
and March 2016. Studies reporting specific outcomes of patients treated for Crohn’s anal fistula were
included. The primary outcome was fistula healing rate. Bias was assessed using the Cochrane ROBINS-I
and ROB tool as appropriate.
Results: A total of 1628 citations were reviewed. Sixty-three studies comprising 1584 patients were
ultimately selected in the analyses. There was extensive reporting on the use of setons, advancement
flaps and fistula plugs. Randomized trials were available only for stem cells and fistula plugs. There was
inconsistency in outcome measures across studies, and a high degree of bias was noted.
Conclusion: Data describing surgical intervention for Crohn’s anal fistula are heterogeneous with a high
degree of bias. There is a clear need for standardization of outcomes and description of study cohorts for
better understanding of treatment options.
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Introduction
Crohn’s disease affects an estimated 145 per 100 000
people in the UK1. One in three of these patients will
develop a perianal fistula2, of whom just one in three
achieve long-term healing of the fistula3. This is a con-
dition that should be managed in concert between sur-
geon and physician4. Published guidelines advocate sepsis
control and use of anti-tumour necrosis factor (TNF) α
therapy5,6. Some patients improve or heal with this treat-
ment, although many require further surgical intervention.
The selected intervention may vary, depending on whether
the treatment aim is cure or symptom relief.
Previous studies have shown that a range of surgi-
cal techniques are employed7. These include the use of
a draining seton, anal fistula plug, fistulotomy, stoma
creation and proctectomy. Newer techniques such as
video-assisted anal fistula treatment (VAAFT; Karl Storz,
Tuttlingen, Germany) and over-the-scope clip (OTSC®;
Ovesco Endoscopy, Tübingen, Germany) have also been
introduced. This variation in practice suggests either that a
widely acceptable and reproducible procedure has not yet
been identified, or that additional factors may influence
choice.
There is no current systematic assessment of all poten-
tial surgical interventions for the treatment of Crohn’s anal
fistula. The aim of this reviewwas to collate data on the out-
comes, including complications, of surgical interventions
for the treatment of fistulating Crohn’s anal disease.
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Methods
Search strategy
A systematic literature search for all publications that
reported a Crohn’s anal fistula-specific outcome, or
surgical treatment outcomes of Crohn’s anal fistula pub-
lished between 1995 and March 2016 was performed.
Since 1995, supporting medical therapy has changed
significantly8. MEDLINE, Embase and Cochrane Library
databases were searched using a predefined and regis-
tered (PROSPERO database, CRD42016050316) search
protocol. Original studies were eligible for inclusion.
Hand-searching was limited to bibliographies from iden-
tified systematic reviews following experiences in the pilot
searches. Conference proceedings were included when
related full text could be identified. Only papers in English
were included. Manuscripts that reported outcomes of
Crohn’s anal fistula as part of all fistula types, those with
fistula related to ileoanal pouch only, or outcomes of
Crohn’s rectovaginal fistula only, were excluded.
Terms used included ‘Crohn Disease’, ‘Rectal fistula’ or
‘anal fistula’, ‘surgery’, ‘Ligation of inter-sphincteric fistula
tract’ (LIFT), ‘seton’, ‘fistula plug’, ‘advancement flap’,
‘vaaft’, ‘OTSC’ ‘stoma’ and ‘proctectomy’ (Appendix S1,
supporting information).
VAAFT involves insertion of a fistuloscope through the
external opening of the track. Secondary tracks are then
identified and electrocautery is performed through the
scope. The internal opening is identified and closed using
a full-thickness advancement flap, with excision of the
primary track where possible.
The OTSC® technique is performed in the lithotomy
position. The track is prepared using a fistula brush. Anal
mucosa is excised circumferentially around the internal
fistula opening. Sutures are placed into the internal anal
sphincter around the internal fistula opening and all tied
loosely together in a knot with a few centimetres of length.
The knot is then pulled through a clip applicator that
guides a circular nitinol metal clip on to the internal fistula
opening in order to close it.
Data extraction
Inclusion and exclusion criteria were applied to retrieved
citations by two independent reviewers. Abstracts were
reviewed to identify full-text papers. Two reviewers had to
agree on inclusion of an abstract. The same process was
repeated for full-text articles. At this stage, the reason for
exclusion was recorded.
Two reviewers recorded extracted data independently
into a data collection form. These were compared and
any variation was discussed with a third reviewer. Where
data were missing or unclear, the corresponding author was
contacted by e-mail for clarification.
Data items collected included study descriptors, data on
patient cohort, primary outcome used (including defini-
tion) and corresponding event rate. Study descriptors were
year of publication, first author, study design, number of
participants and number of participants with Crohn’s dis-
ease, originating hospital and country of author. Patient
descriptors included mean or median age of patient cohort,
sex, duration of Crohn’s disease, fistula anatomy (defined
using either Parks’ classification or the American Gastro-
enterological Association definition) and, where available,
concurrent medical therapy. Intervention details focused
on the primary surgical intervention, such as seton place-
ment, LIFT procedure or fibrin glue. Primary outcome
was taken as defined by each paper, as was the interval to
assessment. Additional outcomes, including complications,
were recorded as available together with rates of long-term
recurrence.
Quality analysis
The study was conducted according to PRISMA
guidelines9. Risk of bias was assessed using the ROBINS-I
tool for non-randomized interventions10, and the
Cochrane tool for bias assessment in randomized trials11.
Bias was assessed independently by two reviewers and
then reconciled. Where there was disagreement, a third
reviewer acted as an arbiter. The IDEAL (Idea, Devel-
opment, Exploration, Assessment, Long-term study)
framework provides a means of categorizing the develop-
ment stage of an intervention12. This allows categorization
according to how technically developed a technique is,
how well the indications are defined, what the risks and
benefits of the procedure are, and long-term follow-up
data. Studies were assessed by two authors and allocated to
an IDEAL stage.
Statistical analysis
Although meta-analyses of the data were originally
intended, the paucity of RCTs and prevalence of small
case series led to the decision to perform a qualitative
synthesis only using descriptive statistics. No assessment
of heterogeneity, publication bias or any other statistical
assessment was planned. The primary outcome was fistula
healing rate, defined as a reduction of 50 per cent or
more from baseline in the number of draining fistulas
observed at two or more consecutive study visits, as per
the ACCENT-II study8.
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Records identified through database
searching
n = 1628
Additional records identified through
other sources
n = 0
Records after duplicates removed
n = 837
Records screened
n = 837
Records excluded
n = 685
Full-text articles assessed
for eligibility
n = 152
Studies included in
qualitative synthesis
n = 63
Studies included in
quantitative synthesis
(meta-analysis)
n = 0
Full-text articles excluded n = 89
 Crohn’s outcomes not reported separately n = 24
 Meeting abstract n = 21
 Surgical outcomes not reported n = 14
 Not in English n = 11
 No surgical intervention described n = 4
 Operation type not defined n = 4
 Case report n = 3
 Report of non-fistula perianal complications n = 3
 Paediatric study n = 2
 Review article n = 2
 Editorial n = 1
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Fig. 1 PRISMA flow chart showing selection of studies for review
Results
Search results
Initial literature review identified 1628 citations, of which
791 were duplicates. Screened against the eligibility crite-
ria, full-text manuscripts were retrieved and assessed. Of
these 152 articles, 63 were included in the qualitative syn-
thesis, reporting outcomes involving 1584 patients (Fig. 1).
Study design was defined as retrospective cohort in 39
studies, as prospective cohort in 16, and as open-label or
single-arm trial in five; there were three RCTs. The num-
ber of patients with Crohn’s anal fistula ranged from two to
41 in prospective cohort studies, one to 119 in retrospec-
tive cohorts, and ten to 33 in open-label/single-arm
trials. There were 141 patients in the randomized
trials.
The surgical interventions described were draining
seton, examination under anaesthesia (EUA) with local
anti-TNFα therapy, fistulotomy, fistulectomy, fistula plug,
fibrin glue, advancement flap, LIFT procedure, VAAFT,
OTSC®, carbon dioxide laser therapy, diverting stoma and
proctectomy. A summary of study characteristics is shown
in Table 113–75.
Risk of bias within studies
Bias assessment for non-randomized and randomized stud-
ies is shown in Tables S1 and S2 (supporting information).
Overall, bias in non-randomized studies tended to decrease
as publication dates approached the present. Potential bias
from confounders arose in studies with mixed popula-
tions (cryptoglandular and Crohn’s fistula), with incom-
plete characterization of the cohort. This bias was reduced
in cohorts limited to Crohn’s fistula, where patient and
disease factors were usually more clearly defined. Charac-
terization was still suboptimal with regard to classification
of fistulas, use of medical therapies, distribution of disease,
smoking status and duration of perianal fistula.
Selection bias was an issue in retrospective studies that
reported the outcomes of interventions in a single centre
over a number of years. The criteria for offering inter-
ventions to patients were not clear: several studies stated
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Table 1 Summary of included studies
Reference Study design
Total no. of
patients
No. of patients
with Crohn’s
anal fistula Intervention(s)
Buchanan et al.13 Retrospective cohort 24 6 Seton
Chung et al.14 Retrospective cohort 51 40 Seton, AFP
Gligorijevic´ et al.15 Prospective cohort 24 24 Seton
Göttgens et al.16 Pilot trial 10 10 Seton
Kotze et al.17 Retrospective cohort 78 78 Seton
Sciaudone et al.18 Retrospective cohort 35 35 Seton
Sugita et al.19 Retrospective cohort 67 67 Seton
Tanaka et al.20 Retrospective cohort 14 14 Seton
Uchino et al.21 Retrospective cohort 62 62 Seton
Graf et al.22 Retrospective cohort 119 119 Seton, fistulotomy
Thornton and Solomon23 Retrospective cohort 28 28 Seton
Dursun et al.24 Retrospective cohort 81 81 Seton, fistulotomy
Alessandroni et al.25 Prospective cohort 12 12 Local anti-TNFα
Asteria et al.26 Prospective cohort 11 11 Local anti-TNFα
Faucheron et al.27 Retrospective cohort 41 41 Fistulotomy, seton
Halme and Sainio28 Retrospective cohort 35 35 Fistulotomy
Scott and Northover29 Retrospective cohort 59 59 Fistulotomy, seton
van Koperen et al.30 Retrospective cohort 61 61 Fistulotomy, MAF
de Parades et al.31 Retrospective cohort 30 11 Fibrin glue
Sentovich32 Retrospective cohort 48 6 Fibrin glue
Sentovich33 Retrospective cohort 40 4 Fibrin glue
Park et al.34 Prospective cohort 25 2 Fibrin glue
Loungnarath et al.35 Retrospective cohort 39 13 Fibrin glue
Zmora et al.36 Retrospective cohort 37 7 Fibrin glue, MAF
Mizrahi et al.37 Retrospective cohort 106 28 MAF
Hyman38 Prospective cohort 33 14 MAF
Jarrar and Church39 Retrospective cohort 98 19 MAF
Joo et al.40 Retrospective cohort 26 26 MAF
Makowiec et al.41 Prospective cohort 32 32 MAF
Ozuner et al.42 Retrospective cohort 101 47 MAF
Rieger et al.43 Retrospective cohort 35 6 MAF
Sonoda et al.44 Retrospective cohort 99 44 MAF
Marchesa et al.45 Retrospective cohort 13 13 MAF
Van der Hagen et al.46 Retrospective cohort 103 21 MAF, fistulotomy
Nelson et al.47 Retrospective cohort 65 17 Dermal advancement
Cintron et al.48 Prospective cohort, multicentre 73 8 AFP
El-Gazzaz et al.49 Retrospective cohort 33 13 AFP
Ky et al.50 Prospective cohort 45 14 AFP
O’Connor et al.51 Prospective cohort 20 20 AFP
Ommer et al.52 Retrospective cohort 40 4 AFP
Owen et al.53 Retrospective cohort 35 3 AFP
Schwandner and Fuerst54 Prospective cohort 16 10 AFP
Schwandner et al.55 Prospective cohort 19 7 AFP
Senéjoux et al.56 RCT 106 106 AFP, seton
Zubaidi and Al-Obeed57 Prospective cohort 22 2 AFP
Gingold et al.58 Prospective cohort 15 15 LIFT
Molendijk et al.59 Randomized phase II trial 21 21 MSC
Cho et al.60 Phase I trial 10 10 ASC
Cho et al.61 Prospective cohort 41 41 ASC
Ciccocioppo et al.62 Phase I trial 12 12 MSC
de la Portilla et al.63 Open-label trial 24 24 ASC
Garcia-Olmo et al.64 Prospective cohort 10 3 ASC
Garcia-Olmo et al.65 Randomized open-label trial 49 14 ASC, fibrin glue
Lee et al.66 Phase II trial 43 33 ASC
Schwandner67 Prospective cohort 13 11 VAAFT
Mennigen et al.68 Retrospective cohort 10 6 OTSC®
Regueiro and Mardini69 Retrospective cohort 32 32 EUA
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Table 1 continued
Reference Study design
Total no. of
patients
No. of patients
with Crohn’s
anal fistula Intervention(s)
Schlegel et al.70 Retrospective cohort 11 11 IAR
Yamamoto et al.71 Retrospective cohort 31 31 Stoma
Schaden et al.72 Retrospective cohort 69 5 Myocutaneous flap
Ozturk73 Retrospective cohort 10 1 Free cartilage
Bodzin74 Retrospective cohort 7 7 Carbon dioxide laser
Moy and Bodzin75 Retrospective cohort 27 27 Carbon dioxide laser
AFP, anal fistula plug; TNF, tumour necrosis factor; MAF, mucosal advancement flap; LIFT, ligation of intersphincteric tract; MSC,
mesenchyme-derived stem cells; ASC, adipose-derived stem cells; VAAFT, video-assisted anal fistula treatment; OTSC, over-the-scope clip; EUA,
examination under anaesthesia; IAR, intersphincteric anal resection.
that patients offered a procedure ‘typically’ had certain
characteristics. Studies from teaching hospitals reported
outcomes of patients referred to their centre, likely to
introduce further selection bias.
Bias associated with the classification of interventions
tended to be low in studies reporting outcomes from one
specific procedure. The details of the procedure and peri-
operative care were clear. In studies reporting the use of
setons, some issues arose around the timing of removal,
whether setons were removed or not, and the timing and
nature of concurrent medical therapy15,17.
Outcomemeasurement was highly variable.Many studies
reported healing, without clear definition, as their primary
outcome. Other commonly reported measures included
absence of drainage from a fistula when compressed with
a finger56, or closure of the external and internal opening
of a fistula track at variable time points. Occasional use
of MRI to confirm fistula fibrosis was reported25. One
study29 reported a successful outcome as ‘the patient and
surgeon are both satisfied’. Only one study56 had blinded
assessors – a panel of three surgeons who reviewed peri-
neal photographs to confirm fistula closure.
In the randomized trials, themain concerns involved allo-
cation concealment and blinding of participants. One stem
cell study65 had patients allocated to receive liposuction
to harvest cells only if they were in the intervention arm.
Overall, these trials were of good quality.
Results of studies
A summary of the key outcomes by intervention is shown
in Table 2.
Outcomes after seton insertion
Setons were used in a number of different ways.
Use of a seton alone, with removal at various time
points, was reported in six retrospective fistula cohort
studies13,14,18,19,21,22, and included a total of 329 Crohn’s
Table 2 Summary of key outcomes by intervention, including
classification of level of evidence76
Intervention
Highest level
of evidence
Success
rate (%) Complication rate (%)
Seton IIb 14–81 Abscess 7–8
Fistulotomy IIIb 72–100 n.r.
Fibrin glue IIIb 40–67 n.r.
Anal fistula plug IIb 15–86 Abscess 4–54
Avulsion 10
Dehiscence 2
Advancement flap IIIc 50–85 Haematoma 7
Flap retraction 7
LIFT procedure IV 60 n.r.
Local stem cells Ib 29–79 Pain 19
Anal inflammation 7
Abscess 17–19
VAAFT IV 8 n.r.
OTSC® IV 83 n.r.
Stoma IIc 81 Death 5
Stoma complication 16
n.r., Not reported (used where no outcomes reported, or outcomes in
patients with Crohn’s disease not clear); LIFT, ligation of intersphincteric
tract; VAAFT, video-assisted anal fistula treatment; OTSC,
over-the-scope clip.
fistulas. In the four studies14,18,19,22 assessing short-term
healing, success rates ranged from 14 to 81 per cent.
One study21 looked at symptom improvement, defined
as improvement by at least 1 point in all domains of the
perianal disease activity index. This endpoint was achieved
in 72 per cent of patients. Long-term recurrence was
reported in 43 per cent18 and 83 per cent13 of patients.
Further drainage of abscess was required in 42⋅8 per cent19,
and in one study21 two patients developed a cancer related
to the fistula.
Long-term setons were used for symptom control in
one study23 of 28 patients, of whom 26 noted symp-
tomatic improvement. The two patients without improve-
ment went on to have a proctectomy or defunctioning
stoma.
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Seton therapy combined with anti-TNFα therapy was
the focus of two retrospective cohort studies17,20 and one
prospective cohort study15, accounting for a total of 116
patients. There was incomplete characterization of group
demographics. The timing of anti-TNFα therapy in rela-
tion to sepsis drainage or seton insertion was not clear in
these studies. Short-term success was defined as absence
of drainage in two studies15,17 (although the time point
for measurement was unclear) and complete fistula heal-
ing in one20. These outcomes were achieved in 46 per
cent15, 53 per cent17 and 79 per cent20 of patients. Recur-
rence rates, where reported, were between 9 and 28 per
cent15,20. Abscesses occurred in up to 8 per cent15. One
study20 reported no serious adverse effects related to sys-
temic drug therapy. Seton with anti-TNFα therapy also
formed the control arm of a randomized trial56, which
found short-term healing in 30⋅7 per cent of patients, with
a recurrent abscess rate of 7⋅7 per cent.
Examination under anaesthesia with local or systemic
anti-TNFα therapy
Two prospective studies25,26 assessed responses to EUA
and local injection of anti-TNFα drugs. In one study26,
11 patients received between three and five injections,
and eight patients achieved remission (cessation of fistula
drainage) at the end of the treatment course. In the second
study25, 12 patients with Crohn’s anal fistula underwent
fistulectomy and local anti-TNFα injection. Definition
of healing was based on clinical and MRI appearances
at 1 year. With four patients lost to follow-up, healing
was achieved in seven patients (88 (95 per cent c.i. 48
to 100) per cent). One patient developed a new perianal
abscess and another developed pulmonary tuberculosis
after treatment25.
One retrospective study69 assessed the use of EUA as
an adjunct to systemic anti-TNFα therapy, and found no
discharge from fistulas at 3months, although subsequent
recurrence occurred in 44 per cent.
Fistulotomy
Seven retrospective studies22,24,27–30,46 reported on the
outcomes of fistulotomy in 148 patients. Although baseline
factors were poorly reported, these were typically for low
fistulas – those involving a small part of sphincter where
division would not alter function. Outcomes were defined
as initial healing22 or 3-month healing24.
Short-term healing was successful in 72–100 per cent
of patients22,24,27,28. Longer-term (6months or more
after treatment) fistula recurrence occurred in five of 28
patients30 and three of nine patients46 at 12months. One
study29 found that 22 of 27 patients had a ‘satisfactory’
outcome, although the five patients in whom the out-
come was unsuccessful developed significant incontinence.
Higher rates of continence disturbance were seen in other
studies30.
Fibrin glue
Six studies (five retrospective31–33,35,36 and one
prospective34) included 219 patients, but only 43 of
these had Crohn’s disease. Short-term success rates for
fibrin glue ranged from 40 to 67 per cent31,33,34,36. In
one study32 reporting long-term follow-up, three of four
patients remained healed.
Fistula plug
Results of anal fistula plug were reported in 11 stud-
ies including 191 patients with Crohn’s anal fistula.
Study design included one RCT56, six prospective
cohort studies48,50,51,54,55,57 and four retrospective cohort
studies14,49,52,53. In the cohort studies, follow-up ranged
from 0⋅75 to 29months after the procedure. Definition of
demographics was poor in these studies, and included 14
patients with a complex fistula in one study50 (including 4
rectovaginal fistulas), and patients with a single transphinc-
teric track and no proctitis in another55. In the RCT, the
American Gastroenterological Association classification77
was used, and included 18 patients with a complex fistula
and 78 with a simple fistula. Ratios of men to women were
3 : 1 and 41 : 68 where reported, and age ranged from 26 to
43 years. Disease duration before the RCTwas 3–13 years.
One study54 included the use of faecal diversion in addition
to the anal fistula plug in some patients.
Success rates for the fistula plug technique ranged from
15 to 86 per cent. Where reported49,50,52,56, postoper-
ative abscess formation occurred in 4–54 per cent of
patients. Additional complications included one wound
dehiscence52, five plug extrusions and two episodes of sig-
nificant pain56.
Advancement flaps
Eight retrospective30,37,39,40,42–44,46 and two prospective
observational38,41 studies reported the outcome of mucosal
advancement flaps in both Crohn’s and cryptoglandu-
lar perianal fistulous disease. Of the 590 reported pro-
cedures, 204 were performed for Crohn’s fistula. Where
reported, treated fistulas were predominantly transphinc-
teric, although studies included some rectovaginal fistulas.
Success in short-term healing was observed in 50–85 per
cent of patients.Where reported38,46, the recurrence rate at
more than 1 year was 30–50 per cent. Complications were
reported in only one study40, with haemorrhage and flap
retraction occurring in 7 per cent.
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A retrospective study45 reported on the use of a cir-
cumferential advancement flap for severe and multiple fis-
tula tracks in 13 patients, combined with stoma formation
in eight. This led to symptomatic improvement in eight
patients, although all patients also had a stoma either before
or as part of the procedure.
One retrospective study47 reported on the use of dermal
flaps to close the fistula opening, with 15 of 17 patients
achieving short-term healing.
An augmented approach was used in a pilot trial16. This
involved placement of a seton, followed by local treatment
with platelet-rich plasma and mucosal advancement flap.
Participants also received multiple concomitant medical
therapies. At 1-year follow-up, seven of the ten patients had
a dry fistula.
Ligation of intersphincteric fistula tract procedure
One study58 reported the outcomes of patients undergoing
the LIFT procedure. This was a retrospective study of 15
patients with transphincteric fistula, followed up for 1 year.
At 2-month follow-up, nine (60 per cent) had healed, and
eight of these remained healed at 1 year. Complications
such as abscess were reported for this study; however, they
were calculated as mean numbers for the cohort. The
author was contacted, but data from this study were no
longer available.
Stem cell therapy
Six studies reported the outcome of stem cell therapy; five
open label/phase I or II trials59,60,63,65,66, with longer-term
follow-up61 of the cohort initially reported by Cho et al.60
in 2013. These studies assessed adipose-derived stem cells
in 143 patients. One phase I trial62 reported outcomes of
mesenchymal stem cell treatment in 12 patients. Follow-up
in these studies ranged from 8weeks to 24months. Cohorts
were dominated by men and young patients, with a median
age of about 32 years in several studies. Duration of Crohn’s
disease was approximately 4⋅5 years where reported. Most
fistulas were transphincteric. Success rates for healing
ranged from 29 to 79 per cent. Improvement in symp-
toms was noted in a large proportion of patients. This was
assessed at 8weeks60, defined as a variable time point of ‘no
discharge for 6weeks’59, or at clinic appointments at 12 and
24months61.
Symptoms associated with disease flare, such as abdomi-
nal pain and diarrhoea, were reported in up to 60 per cent66
and 7 per cent61 respectively. Local complications included
anal pain in 19 per cent66, anal inflammation in 7 per cent61,
perianal swelling in 29 per cent59 and perianal abscess in
17–19 per cent59,66 of patients.
A single study64 of recurrent anal fistula with a sub-
group of three patients with Crohn’s disease found that
one patient healed and one improvedwhen adipose-derived
stem cells were injected into the fistula and the internal
opening was closed.
Video-assisted anal fistula treatment
One prospective study67 reported outcomes of patients
treated with VAAFT. Thirteen patients were treated, of
whom 11 had anal fistula related to Crohn’s disease. Of
these 11 fistulas, nine were transphincteric, one was supra-
sphincteric and one was rectovaginal. The mean age of
patients was 34 years. This study67 combined VAAFT with
rectal advancement flap and faecal diversion. ‘Short-term
success’ was achieved in nine patients. There was no report-
ing of complications.
Over-the-scope clip (OTSC R©)
A single case series68 reported the use of OTSC® in anal
fistula. Of the ten patients treated, six had fistula asso-
ciated with Crohn’s disease. Four were women, and all
had a transphincteric fistula. No information was available
on mean duration of disease. Median follow-up was 230⋅5
(range 156–523) days. The study reported short-term heal-
ing in five of the six patients with Crohn’s disease. It was not
possible to extract complications specific to treated patients
with Crohn’s fistula.
Proctectomy and diversion
One retrospective study70 reported the use of intersphinc-
teric anal resection (IAR) for fistulating and fibrosing peri-
anal Crohn’s disease. In this series, 11 patients underwent
IAR and five achieved closure of the fistula. Another retro-
spective study72 assessed outcomes of proctectomy with
one-stage myocutaneous reconstruction (gracilis) in five
patients. Perianal fistula healed in four cases, and only
two patients were free from complications at the end of
follow-up (median 19⋅6months).
Faecal diversion was reported as a sole intervention in a
series of 31 patients71. In this cohort, 25 patients achieved
early remission, although this was sustained in only eight
(median follow-up 81months). One patient died as a result
of Fournier’s gangrene and five developed stoma complica-
tions, of whom two required operative revision. No patient
developed malignancy in the defunctioned rectum71.
Other therapies
One retrospective study75 reported outcomes of patients
treated with carbon dioxide laser to the fistula track. This
included 27 patients, with a mean duration of disease of
36months. At 1-month follow-up, four patients had ceased
fistula drainage. Another retrospective study74 found that
laser treatment healed or improved symptoms in five of six
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Table 3 Interventions classified by the IDEAL framework
IDEAL stage Intervention
1 (Idea) Circumferential advancement flap
VAAFT
OTSC®
Free cartilage
2a (Development) Local anti-TNFα injection
LIFT
Carbon dioxide laser
2b (Exploration) Local stem cell therapy
Mucosal advancement flap
Fibrin glue
3 (Assessment) Anal fistula plug
4 (Long-term study) Seton
Fistulotomy
Stoma/proctectomy
VAAFT, video-assisted anal fistula treatment; OTSC, over-the-scope clip;
TNF, tumour necrosis factor; LIFT, ligation of intersphincteric tract.
patients. One other study73 assessed the use of free cartilage
as an interposition material in Crohn’s fistula. This was
unsuccessful.
Grading according to the IDEAL framework
Only seton, fistulotomy and faecal diversion/proctectomy
are classified as IDEAL 4 interventions. The majority of
interventions are classified as IDEAL 1–2b interventions
(Table 3).
Discussion
Advances in the medical therapy of fistulating perianal
Crohn’s disease have been boosted by large RCTs8,78,79.
The present study has highlighted a number of important
features regarding surgical interventions. The level of
evidence supporting these interventions was generally low.
Studies often captured specific subsets of patients, and
selection bias means that reported results are not always
matched by real-world experience. The lack of a classifi-
cation system with prognostic value means that a benefit
produced in one (unknown and undefined) cohort may be
masked by failure in another. Options for surgical man-
agement of Crohn’s anal fistula, including seton insertion,
advancement flap, anal fistula plug and stem cells, have
been used in several studies, although success rates vary.
Only three RCTs comparing therapies were retrieved.
It should be noted that a number of feasibility studies
were performed, particularly in relation to local stem cell
therapy. Since searches for this review were performed, a
randomized trial of stem cells has been reported80. A ran-
domized trial of advancement flap versus seton drainage in
the context of protocolled medical therapy is underway81.
Meta-analyses were not appropriate for these data. The
IDEAL classification was used to grade the interventions.
Part of the categorization used in the IDEAL framework
is the number and type of patients, with ‘indication’
being an important discriminator12. Although draining
setons, fistulotomy and faecal diversion seem to have
broadly agreed indications with long-term follow-up,
this does not appear to be the case for other interven-
tions. Classification of fistula anatomy varies between the
Hughes–Cardiff classification82, Parks classification83 and
American Gastroenterological Association definitions77.
It is not always possible to consolidate these classi-
fications. Some studies also specified whether or not
patients had proctitis55, as this is thought to be relevant
to prognosis5,6.
Current thinking suggests that optimal therapy involves
a combined medical and surgical strategy. Smaller case
series often described the current medical therapy of their
patients, but larger retrospective studies typically failed to
report this.
It was impossible to make meaningful comparisons of
success rates between interventions, as selected outcomes
and time points were heterogeneous. Pooled analysis was
hampered by the bias inherent in the preponderance of
retrospective studies, and the limited size of their cohorts.
It was impossible to compare risk between the opera-
tive procedures, as reporting of complications was very
poor, with the exception of clinical trials. Some studies30,71
also reported ‘long-term recurrence’ at the end of their
follow-up period as late as 6–8 years, but was this truly
recurrence due to the surgical procedure or simply the nat-
ural history of the disease?
Only broad conclusions can be drawn from the present
study. Setons provide palliation and can be used in the
long term; advancement flap and stem cell therapy may
emerge as effective therapies, but require well designed
randomized trials. A number of other procedures including
LIFT, VAAFT and OTSC® require further evaluation.
Fibrin glue has largely fallen out of favour, and fistula
plugs are considered to have limitations, including failure
and associated sepsis. Advancement flaps may not be tech-
nically possible with a ‘woody’ rectum, extensive fibrosis or
active proctitis. The combination of recurrent Crohn’s dis-
ease and loose stool means that any sphincter disruption
or alteration in anocutaneous sensation may have an exag-
gerated impact on continence. Clinicians and patients may
therefore understandably be keen to avoid procedures that
pose additional risk to the sphincter, including fistulotomy.
Given these technical considerations, fistula anatomy and
the risk of recurrent episodes of anal perianal sepsis, includ-
ing fistula in the long term, it is unsurprising that most
© 2017 The Authors. www.bjsopen.com BJS Open 2017; 1: 55–66
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clinicians favour conservative interventions such as seton
placement7.
When considering these studies together, especially over
longer-term follow-up, it may be inferred that Crohn’s
anal fistula is at best palliated by surgical intervention.
Most studies report success in terms of short-term healing,
and have not addressed the management or prevention of
long-term recurrence. Although the idea of healing anal
fistula is aspirational, work is required to understand how
to control symptoms and limit recurrence with medical
and surgical techniques. Patient-centred outcomes such
as data on quality of life, impact on personal and social
interactions, or lost work-days may be more helpful in
decision-making. For example, faecal diversion has been
shown to improve gastrointestine-specific domains of
quality-of-life measures in this setting84.
Work needs to be done to improve the quality of evi-
dence for every type of surgical intervention. Transparent
and thorough reporting on studies involving these patients
is warranted. There needs to be international agreement
on definitions to facilitate comparisons between institu-
tions. Development and adoption of a core outcome set,
including a validated, disease-specific quality-of-life score,
would help. A classification system based on prognostic
factors, and improved therapeutic options based on an
understanding of the current mechanisms of treatment
failure, are both crucial.
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This study has systematically reviewed data on outcomes for surgery in Crohn’s anal fistula. Studies have heterogenous outcomes
precluding meta-analysis. This study highlights factors associated with poor generalizability of findings, which may be built upon by
future researchers in this field.
